JP2008535494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535494A5 JP2008535494A5 JP2008505603A JP2008505603A JP2008535494A5 JP 2008535494 A5 JP2008535494 A5 JP 2008535494A5 JP 2008505603 A JP2008505603 A JP 2008505603A JP 2008505603 A JP2008505603 A JP 2008505603A JP 2008535494 A5 JP2008535494 A5 JP 2008535494A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- prlr
- expression
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 45
- 238000000034 method Methods 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 20
- 101150015730 Prlr gene Proteins 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 13
- 102100029000 Prolactin receptor Human genes 0.000 claims 13
- 239000012472 biological sample Substances 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 9
- 208000026310 Breast neoplasm Diseases 0.000 claims 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 9
- 206010060862 Prostate cancer Diseases 0.000 claims 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims 9
- 201000005202 lung cancer Diseases 0.000 claims 9
- 208000020816 lung neoplasm Diseases 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 201000000849 skin cancer Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000009739 binding Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002853 nucleic acid probe Substances 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 claims 1
- 102000003946 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 102000044437 S1 domains Human genes 0.000 claims 1
- 108700036684 S1 domains Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66986105P | 2005-04-07 | 2005-04-07 | |
| PCT/US2006/013160 WO2006110585A2 (en) | 2005-04-07 | 2006-04-07 | Cancer-related genes (prlr) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535494A JP2008535494A (ja) | 2008-09-04 |
| JP2008535494A5 true JP2008535494A5 (enExample) | 2009-04-02 |
Family
ID=36809257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505600A Pending JP2008535853A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子 |
| JP2008505603A Pending JP2008535494A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子（ｐｒｌｒ） |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505600A Pending JP2008535853A (ja) | 2005-04-07 | 2006-04-07 | 癌関連遺伝子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090220495A1 (enExample) |
| EP (3) | EP1871911A2 (enExample) |
| JP (2) | JP2008535853A (enExample) |
| AU (1) | AU2006235258A1 (enExample) |
| CA (1) | CA2604844A1 (enExample) |
| WO (2) | WO2006110581A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| KR20090003178A (ko) | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| JP2009536834A (ja) | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| US20100021424A1 (en) * | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| EP3018144A1 (en) * | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| US20100240035A1 (en) * | 2007-06-01 | 2010-09-23 | The Regents Of The University Of California | Multigene prognostic assay for lung cancer |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| EP2227556B1 (en) * | 2007-11-19 | 2014-08-27 | Celera Corporation | Lung cancer markers and uses thereof |
| CA2718854A1 (en) * | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| BRPI0912683A2 (pt) | 2008-05-15 | 2016-01-26 | Transmolecular Inc | tratamento de tumores metastáticos |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| EP3115063A3 (en) * | 2008-12-03 | 2017-04-19 | The John Hopkins University | Galectin-3 and annexin-a2 as immunological target |
| WO2010127322A1 (en) | 2009-05-01 | 2010-11-04 | Genomic Health Inc. | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013044164A1 (en) * | 2011-09-21 | 2013-03-28 | The Regents Of The University Of California | Methods to treat and/or prevent relapse in notch1-driven malignancies |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| EP2812350B1 (en) * | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013166153A2 (en) * | 2012-05-01 | 2013-11-07 | Brentnall Teri | Methods and compositions for cancer diagnosis |
| KR102082099B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140179560A1 (en) | 2012-12-10 | 2014-06-26 | Fred Hutchinson Cancer Research Center | Drug discovery methods and platforms |
| TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與ｗｎｔ抑制劑相關之標記 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| EP3091999B2 (en) | 2014-01-09 | 2025-05-07 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| JP2020529870A (ja) | 2017-08-10 | 2020-10-15 | ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル | がんを層別化し、処置するための材料及び方法 |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
| KR101890392B1 (ko) * | 2018-05-28 | 2018-08-21 | 의료법인 성광의료재단 | Ｗｎｔ３ａ를 포함하는 난소암의 진단을 위한 마커 및 조성물 |
| KR20200115883A (ko) * | 2019-03-28 | 2020-10-08 | 황인후 | 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| US20220326243A1 (en) * | 2019-05-21 | 2022-10-13 | Acurasysbio Co., Ltd. | Composition for cancer diagnosis |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| EP4081253A4 (en) * | 2019-12-25 | 2023-09-06 | Shanghai XBH Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN114487418A (zh) | 2022-02-17 | 2022-05-13 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | TGFb RIII蛋白作为胃癌血清生物标志物的应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| CA2049028A1 (en) | 1989-03-07 | 1990-09-08 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| RU2142467C1 (ru) | 1990-07-27 | 1999-12-10 | Чирон Диагностикс Корпорейшн | Полинуклеотиды, способ их получения, гибридизационный анализ нуклеиновой кислоты |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP3337214B2 (ja) | 1990-12-20 | 2002-10-21 | アーチ・ディベロップメント・コーポレーション | 電離線による遺伝子発現の調節 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| EP1295952A3 (en) | 1996-01-23 | 2003-07-09 | The Board of Trustees of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| WO2002050098A2 (en) * | 2000-12-18 | 2002-06-27 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the prlr gene |
| US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP1466016A2 (en) * | 2002-01-09 | 2004-10-13 | Riken Institute Of Physical And Chemical Research | Cancer profiles |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP2233572A3 (en) * | 2002-06-06 | 2011-01-12 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human colon cancers |
| WO2004016317A1 (en) * | 2002-08-14 | 2004-02-26 | Erasmus University Medical Center Rotterdam | Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| PL1651162T3 (pl) | 2003-05-20 | 2016-04-29 | Immunogen Inc | Maitansynoidy w leczeniu nowotworów |
| WO2004105573A2 (en) * | 2003-05-21 | 2004-12-09 | The Wistar Institute Of Anatomy And Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| JP2006526998A (ja) * | 2003-06-12 | 2006-11-30 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 胃癌および転移性胃癌診断キット |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| JP2005073548A (ja) * | 2003-08-29 | 2005-03-24 | National Cancer Center-Japan | 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用 |
| JP2007506425A (ja) * | 2003-09-24 | 2007-03-22 | オンコセラピー・サイエンス株式会社 | 肝細胞癌を診断する方法 |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP1805519B1 (en) * | 2004-09-21 | 2013-11-06 | Rhode Island Hospital | Wnt proteins and detection and treatment of cancer |
-
2006
- 2006-04-07 JP JP2008505600A patent/JP2008535853A/ja active Pending
- 2006-04-07 JP JP2008505603A patent/JP2008535494A/ja active Pending
- 2006-04-07 CA CA002604844A patent/CA2604844A1/en not_active Abandoned
- 2006-04-07 EP EP06749567A patent/EP1871911A2/en not_active Ceased
- 2006-04-07 EP EP09001181A patent/EP2083088A3/en not_active Withdrawn
- 2006-04-07 WO PCT/US2006/013153 patent/WO2006110581A2/en not_active Ceased
- 2006-04-07 US US11/910,837 patent/US20090220495A1/en not_active Abandoned
- 2006-04-07 AU AU2006235258A patent/AU2006235258A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013160 patent/WO2006110585A2/en not_active Ceased
- 2006-04-07 EP EP06749562A patent/EP1910557A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535494A5 (enExample) | ||
| KR102252332B1 (ko) | 암 전이의 예후 및 치료 방법 | |
| US20230381209A1 (en) | Therapeutic treatment of breast cancer based on c-maf status | |
| JP5926487B2 (ja) | ＥｒｂＢ療法に耐性である癌を治療するための方法 | |
| KR102226219B1 (ko) | 폐암 전이의 진단, 예후 및 치료 방법 | |
| DK3055429T3 (en) | Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer | |
| Remmelink et al. | Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue | |
| KR20150122731A (ko) | 암 전이의 예후 및 치료 방법 | |
| KR20200104298A (ko) | c-MAF 상태에 기반한 유방암의 요법 치료 | |
| TWI567391B (zh) | 辨識早期肺腺癌病患之次群組之生物標記 | |
| Strelau et al. | Expression and putative functions of GDF-15, a member of the TGF-β superfamily, in human glioma and glioblastoma cell lines | |
| ITCH20120008A1 (it) | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate | |
| CN102947446A (zh) | 肺腺癌的预后预测方法、肺腺癌的检测试剂盒以及用于治疗肺腺癌的医药组合物 | |
| JP2008535491A5 (enExample) | ||
| JP2008535855A5 (enExample) | ||
| JP2009523004A5 (enExample) | ||
| CN111440870B (zh) | CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用 | |
| JP2008535854A5 (enExample) | ||
| WO2017012944A1 (en) | Method for individualized cancer therapy | |
| JP2007077155A5 (enExample) | ||
| KR102897399B1 (ko) | 유방암 진단을 위한 신규 바이오마커 | |
| Shaker et al. | Tenascin-C as a new marker for the diagnosis and treatment monitoring of breast cancer. | |
| CA2742512A1 (en) | Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors | |
| ES2527926T3 (es) | HER3 activado como marcador para predecir la eficacia terapéutica | |
| HK40026235A (en) | Therapeutic treatment of breast cancer based on c-maf status |